Skip to main content

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Recruiting · Phase 3 · NCT06742996

Conditions: Mantle Cell Lymphoma, B Cell Lymphoma

At a glance

Research payments reported, 2025
$3.6M
U.S. investigators named
39
Sites paid
42
Planned or actual enrollment
300

About the trial

Sponsor
BeOne Medicines
Tested
Sonrotoclax (drug), Zanubrutinib (drug), Placebo (drug)
Dates
Started 2025-03-05; completion 2032-03-30
Results posted
Not yet

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

From ClinicalTrials.gov, last updated 2026-10-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines Ltd. reported $3.6M in research payments for this study in 2025 (145 payments).

Products named: Brukinsa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.